Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...